Psychotropic use is an area of longstanding concern in the Residential Aged Care sector, and there has been a plethora of guidelines, resources and research projects aimed at changing prescription and usage practices. Despite the abundance of literature examining psychotropics, there is relatively little discourse or critical discussion around informed consent for these drugs. From a practice perspective, significant time and resources are invested in the completion of psychotropic consent forms and assessments, but there is no apparent evaluation of whether current practices are effective in balancing consumer choice and safeguarding. Similarly, it is unclear if current practices adequately provide decision-makers with the correct information needed to truly decide ‘yes’, ‘no’ or ‘maybe’. This presentation will explore current psychotropic informed consent practices based on literature and anecdotal experiences, identify the gaps between current and best practice informed consent, and share information about a research project designed to democratise psychotropic decision-making in aged care. This presentation is aimed at end users and industry practitioners.